October 19, 2017 (HealthDay News) Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration for individuals with certain types of large B-cell lymphoma who have not …
Gene Tx Approved for Certain Types of B-Cell Lymphoma Read More
At a July 2017 FDA Oncology Advisory Committee meeting, the panel reviewed Novartis’ CTL019 (tisagenlecleucel), an agent for aggressive pediatric and young adult acute B-cell acute lymphoblastic leukemia (ALL). The …
CAR T-Cell Therapy HCP Guide – Is CAR T-Cell Therapy Approved? Read More CAR T-Cell FDA Approval: Status Update In addition to the approval of Kymriah, Yescarta (axicabtagene ciloleucel or Axi-Cel) was approved on October 18, 2017 for the treatment of adult patients …
CAR T-Cell Therapy HCP Guide – Updates from the FDA Read More
August 30, 2017 (HealthDay News) Kymriah approved for patients up to 25 years of age with refractory or relapsed B-cell precursor ALL The U.S. Food and Drug Administration on Wednesday …
FDA Approves First Gene Therapy in the United States Read More “The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted to recommend approval for CTL019, an experimental cancer drug that belongs to a class of drugs called CAR …
July 12, 2017 – Novartis CAR-T Cell Therapy One Step Closer to FDA Approval Read More February 28, 2017 (STAT)
Kite Pharma is racing to win approval of their CAR-T cancer therapy. They have posted strong results with their new drug, stating that more than one-third of lymphoma patients are in remission six months after one treatment.
Kite’s CAR-T cancer therapy shows strong results as company races to win FDA approval Read More